A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy

Link to article at PubMed

Immunol Res. 2021 Jan 25. doi: 10.1007/s12026-020-09169-x. Online ahead of print.


Convalescent plasma (CP) therapy is rapidly becoming an established consideration in the treatment of COVID-19 patients though there is a need to critically review this area for proof of efficacy. Neutralizing antibodies (NAb) present in CP generated in response to SARS-CoV-2 infection directed against the receptor-binding domain (RBD) of the spike protein are considered to play main role in viral clearance. CP infusion may also help in the modulation of immune response by its immunomodulatory effect. The FDA allows for administration of CP to COVID-19 patients. The present published literature in COVID-19 is limited to case series and randomised controlled trial where plasma therapy was used in moderate, severe and critically ill patients. Though multiple uncertainties exist regarding to its efficacy, appropriate donor selection and NAb titres, the efficacy data of CP use inCOVID-19 is limited having shown hope with early and severe to critically ill COVID-19 patients.

PMID:33492637 | DOI:10.1007/s12026-020-09169-x

Leave a Reply

Your email address will not be published.